Cheryl Blanchard: Yeah. I’ll tell you the confidence comes from a number of things. We really put some significant energy toward ensuring that we were coming up with a product that addresses true unmet clinical needs. And one of the big pieces of feedback we heard from clinicians was the existing first-generation collagen patches that are in the market today, just don’t provide the kind of strength or suture retention strength, especially when it gets wet which it does immediately intraoperatively. So we address that. We also hear that, there’s obviously always a greater need for increasing the regenerative capacity. We’ve addressed that. There was also a lot of feedback around simplifying surgical technique and instrumentation and fixation to give the surgeon the ability to be efficient and confident in the repair.
And so we’ve really come at it from all directions. We’ve done a number of labs with already a number of surgeons, and the labs have gone incredibly well and we’re really feeling a pull from the surgeon community to get this into their practice. So that’s really what our confidence is based on.
Mike Levitz: And Mike, I’ll speak to the other part of your question around the impact in 2024 and we’ll get more direction on 2024 on our normal schedule. But as Cheryl said, and I said we expect double-digit growth to be continuing here in 2024, and Integrity plays a real solid role in that. We’re excited that that product remains on track to launch in the first quarter. We were very pleased to be able to get the clearance when we did so that we could get everything set to launch here in the first quarter. We’re cognizant, it’s a new product, and it’s going to take a normal ramp that you would expect for a new product. But the team is very excited as Cheryl said, in her comments we really are seeing the pull from the surgeon community, and we’re seeing it from our distributors. And so we’re being very thoughtful about how we’re going to roll that out, but we do expect it to be a meaningful driver of the double-digit growth next year.
Mike Petusky: Okay. And then Mike I guess just a last one for me for now. So your commentary on adjusted EBITDA, I think, I heard you say 6% to 8% this year and then some number higher than that range next year. Was that what you actually meant to say? Or did I not follow that right?
Mike Levitz: Yes, Mike, you have that correct. I said that, our expectation was low single-digit this year. We have raised it now with our progress to date to 6% to 8% is the range for this year, and we expect it to increase next year. We need to see — as we go into next year we’ll hopefully get that feedback from the FDA. We may have some things that we want to focus on here to drive Cingal. But even with all of the different things we’re doing next year now that we are stabilizing the spending and driving the growth of the products that we have now launched, and are launching earlier in the year, we feel confident to say that we’ll be expanding our EBITDA margin next year even as we drive the revenue growth.
Mike Petusky: One quick housekeeping, if you have it in front of you. Is there any chance you have the CapEx beyond this $0.7 million like $728,000? Do you by any chance have that exact figure?
Mike Levitz: The exact figure was $680,000.
Mike Petusky: $680,000. Perfect. Thanks, guys.
Cheryl Blanchard: Thanks, Mike.
Operator: Thank you. And our next question comes from George Sellers with Stephens Inc. Please go ahead.
George Sellers: Hey, thanks for taking the question. Congrats on a good quarter.
Cheryl Blanchard: Thanks, George.
George Sellers: Maybe to start with the Joint Preservation and Restoration segment in the quarter. Could you just give some additional details on the contribution from X-Twist? And you noted RevoMotion contributed as well in the quarter. Just curious how material that contribution is? And then as a follow-on to that for the raised guidance, how much of that is related to the launch of RevoMotion? Thank you.
